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Abstract
Background: Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterised by
progressive renal cyst formation leading to renal failure in the majority of patients. The likelihood and rate of
ADPKD progression is difficult to predict and there is a clear need to identify prognostic indicators that could be
used to anticipate ADPKD progression, to aid the management of patients in clinical practice.
Methods: A systematic literature review was conducted to identify publications detailing the natural history of
ADPKD, including diagnosis, prognosis and progression. Publications were identified and filtered, and data were
extracted, based on a predefined research protocol.
Results: The review identified 2799 journal articles and 444 conference abstracts; 254 articles, including
observational studies, clinical trials and reviews, proceeded to data extraction. Disease progression was associated
with a variety of prognostic indicators, most commonly age and total kidney volume (TKV). In the identified clinical
trials, the absence of a consistent measure of disease progression led to variation in the primary endpoints used.
Consequently, there was difficulty in consistently and effectively demonstrating and comparing the efficacy of
investigational treatments across studies. More consistency was found in the observational studies, where disease
progression was most frequently measured by TKV and glomerular filtration rate.
Conclusions: This systematic review identified age and TKV as the most commonly cited prognostic indicators in
the published ADPKD literature. It is envisaged that this review may inform future research, trial design and
predictive models of ADPKD natural history, helping to optimise patient care.
Keywords: Autosomal dominant polycystic kidney disease, Disease progression, Systematic review, End stage renal
disease, Prognostic indicators
Background
Polycystic kidney disease (PKD) is the most common gen-
etic disorder leading to end stage renal disease (ESRD).
Autosomal dominant polycystic kidney disease (ADPKD) is
caused by germline mutations in PKD1 (85 % of cases) and
PKD2 (15 % of cases), and is typically diagnosed later in life
than autosomal recessive polycystic kidney disease [1–4].
ADPKD is characterised by the progressive development
of multiple bilateral renal cysts and has a prevalence of
less than five patients per 10,000 of the population in the
EU [5–7]. ADPKD is a systemic disease, with extra-renal
manifestations including liver cysts, intracranial aneurysms
and hypertension [3, 8]. Approximately 70 % of patients
with ADPKD will progress to ESRD at a median age of
56 years [9, 10]. Patients with ADPKD may experience
chronic pain, which may be debilitating, in addition to in-
creased morbidity due to enlarged kidneys, which can lead
to poor health-related quality of life (HRQoL) and reduced
social interaction [3, 11].
ADPKD is associated with a high degree of clinical
variability between patients, both within and between fam-
ilies, especially in terms of the likelihood and rate of pro-
gression towards ESRD. In the early stages of ADPKD,
before renal function is significantly compromised, pro-
gression can be difficult to detect as patients are often
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asymptomatic. Currently, there is a lack of consensus in
the published literature regarding the optimal factors for
prediction of renal outcomes and the ideal variables that
should be measured in order to monitor disease progres-
sion, especially in the early stages of the disease. This has
led to difficulties in identifying patients at high risk of
ESRD and in defining appropriate primary endpoints to
consistently measure and compare the efficacy of therap-
ies in development.
There is a requirement for greater understanding of the
predictors of disease progression in ADPKD in order to
optimise clinical trial design, treatment and patient care.
The objective of this systematic review was to identify
publications that detail the natural history of ADPKD,
considering the indicators of early- and late-stage progres-
sion. It was envisaged that this review would aid clinical
practice by informing future research and the develop-
ment of a predictive model to estimate the likely rate of




A systematic review of the literature was conducted to
identify publications that detail the natural history of
ADPKD, including diagnosis, prognosis and progression.
In the absence of a definitive measure of disease progres-
sion, all measures linked to the progression of ADPKD
were considered, although it was anticipated that those
linked to cyst development/renal enlargement and renal
function would be the most relevant.
The systematic review was conducted and reported ac-
cording to the principles in the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
statement [12] (Additional file 1). A search was conducted
in the following electronic databases:
 MEDLINE and MEDLINE In-Process
 Embase
 Cochrane Central Register of Controlled Trials
(CENTRAL)
 The Cochrane Database of Systematic Reviews
(CDSR)
 NHS Economic Evaluation Database (NHS EED)
 Health Economic Evaluations Database (HEED)
 BIOSIS.
Electronic databases were searched on 7th April 2014
using a structured search string, including terms for
ADPKD and study type (Additional file 2). The search
was restricted to publications from the previous 10 years
in all databases except BIOSIS, which was limited to the
past 3 years. Publications in the field of ADPKD have
become significantly more numerous in recent years;
therefore, it was considered that a sufficient number of
relevant articles would be identified and that any earlier
studies containing key information would be identified
through reference explosion. In addition, diagnostic and
prognostic techniques have progressed with the advance-
ment of technology, with earlier publications often rely-
ing on subjective measures of progression, including
kidney palpation.
‘Grey literature’ searches of relevant congresses, limited
to the past 3 years, were also conducted (World Congress
of Nephrology, American Society of Nephrology, American
Academy of Nephrology, British Renal Society, European
Renal Association and International Society for Pharmacoe-
conomics and Outcomes Research). Reference lists of sys-
tematic reviews and meta-analyses identified by the search
were reviewed to identify additional relevant articles that
were not identified in the systematic search due to study
type restrictions.
Studies meeting the following criteria were considered
for inclusion in the review:
 Study types: clinical trials, observational studies,
systematic reviews, meta-analyses and non-
systematic reviews
 Population: human, adults (≥18 years of age) with
PKD, or ADPKD specifically
 Outcomes: diagnosis or prognosis
 Language: English.
Study selection
Identified articles were screened by one reviewer, ac-
cording to the criteria specified above. Articles were fil-
tered using a positive exclusion method, whereby articles
with insufficient information to warrant their exclusion
remained in the review [13].
Initially, titles and abstracts of identified articles were
reviewed (title/abstract screening) according to a check-
list; full-text papers of the publications remaining after
title/abstract screening were reviewed according to the
same checklist (full text screening). Papers assessing
HRQoL were excluded at full text screening if they did
not report data on the progression of ADPKD.
Publications that included assessment of the link
between ADPKD progression and genetic markers were
only included in the review if they assessed the link with
genotype (PKD1/PKD2). Publications assessing genetic
markers at a molecular level, i.e. studies assessing spe-
cific single nucleotide polymorphisms, were excluded
because this level of detail is not readily available to
nephrologists in clinical evaluations. An independent
reviewer checked a random selection of articles (10 %)
at both title/abstract and full text screening to ensure
consistency and accuracy.
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Data extraction
Data were extracted from studies that met the inclusion
criteria. If more than one article was found to present data
from the same study population, results were collated as
appropriate.
Extracted data consisted of:
 Study characteristics, such as study design, duration
and location
 Patient characteristics (see ‘Definitions’)
 Clinical characteristics and outcomes linked to
disease progression (see ‘Definitions’)
 Information regarding ESRD in the patient
populations, such as age at ESRD onset and length
of time on dialysis.
Definitions
For the purposes of this review, ‘patient characteristics’
were demographic data and ‘clinical characteristics’ were
defined as baseline clinical parameters, baseline measures
of renal size and function, and characteristics that were
not influenced by changing renal parameters, e.g. geno-
type (Table 1). ‘Outcomes’ were defined as any measures
or markers of disease progression, such as parameters re-
ported over a time period, or measurements taken at both
baseline and end of the study. The reporting of symptoms
of ADPKD, such as pain, may have been considered as
patient characteristics if only reported at baseline, but may
also have been considered as outcomes if reported over
time.
Glomerular filtration rate (GFR) was a recognised meas-
ure of renal function, and was either estimated based on
serum creatinine concentration using equations such as the
Modification of Diet in Renal Disease (MDRD) equation or
the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation (estimated GFR [eGFR]), or measured
by creatinine clearance (measured GFR [mGFR]). For sim-
plicity, we used the term ‘GFR’ to refer to studies that used
either eGFR or mGFR or both, or where methods of deter-
mining GFR were not defined. Change in GFR was used as
a measure of renal function and change in total kidney vol-
ume (TKV) was used for renal volume in this review.
Results
Figure 1 shows the selection process for articles included in
the systematic review. A total of 2799 articles were identi-
fied in the original literature search, with a further 444 rele-
vant conference abstracts identified. A total of 254 articles
proceeded to the data extraction stage. Of the 254 papers
that progressed to data extraction, 160 were observational
studies, 33 were clinical trials and 61 were reviews.
Observational studies
The majority of the identified studies were observational
studies (63.0 %), including case studies, registry reviews
and patient surveys with durations ranging from 6 months
to more than 40 years. The studies employed a range of
different objectives, with many aiming to increase under-
standing of ADPKD. Most studies reported baseline
patient characteristics, including average age and gender
(65 and 58.8 % of studies, respectively), while symptoms
of ADPKD frequently reported at baseline included hyper-
tension and proteinuria (21.3 and 10.6 % studies, respect-
ively). The most commonly reported measure of renal
function, described in 66 (41.3 %) observational studies,
was GFR. The most frequent measure of renal size was
TKV (34 studies, 21.3 %).
Of the 38 (23.8 %) publications that reported outcomes
of ADPKD measured over time, disease progression was
measured in 32 studies (84.2 %) by GFR, estimated most
commonly by the MDRD equation (41.6 %). Change in
TKV was reported as a measure of disease progression in
12 studies (31.6 %), with 11 publications using magnetic
resonance imaging (MRI) and one publication using com-
puted tomography. Renal enlargement over time as a
surrogate marker of disease progression was also mea-
sured by total cyst volume (TCV) (five studies) [14–18],
volume of each kidney (four studies) [19–22], and total
renal volume (TRV) (three studies) [19, 22, 23].
In total, 19 studies reported patient and clinical char-
acteristics of patients with ESRD. Of these studies, 18
reported age at ESRD and 11 reported the number of
ADPKD patients reaching ESRD. Baseline characteristics
of patients in each of the study groups were not reported
in eight studies [24–31], but others reported a number
Table 1 Patient characteristics and outcomes in ADPKD
Patient characteristics Clinical characteristics Outcomes
Demographic factors: age,
gender, BMI, weight, height,
ethnicity
Baseline renal function parameters: GFR, serum creatinine,
proteinuria, albuminuria, creatinine clearance, albumin/
creatinine ratio
Change in renal function parameters: GFR, serum
creatinine, proteinuria, albuminuria, creatinine clearance,
albumin/creatinine ratio
Baseline renal size parameters: TKV, TCV, TKL, left renal
volume, right renal volume, height-adjusted TKV
Change in renal size parameters: TKV, TCV, TKL, left renal
volume, right renal volume, height-adjusted TKV
Clinical measures: presence of hypertension, renal blood
flow, haematuria, UTI
Change in clinical measures: renal blood flow,
hypertension
Genotype
BMI body mass index, GFR glomerular filtration rate, TCV total cyst volume, TKL total kidney length, TKV total kidney volume, UTI urinary tract infection
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of parameters including age (seven studies) [32–37],
serum creatinine (four studies) [37–40], GFR (three
studies) [33, 35, 38], TKV (three studies) [33, 36, 40],
hypertension (one study) [41] and PKD mutation (one
study) [42].
Publications were identified that measured GFR decline
or increase in TKV (disease progression) and assessed the
associated patient and clinical characteristics, defined in
Table 1. If the association with patient and clinical charac-
teristics was significant, these were then defined as prog-
nostic indicators in the prediction of disease progression
(Table 2).
TKV and age at baseline were the two factors most com-
monly cited as significantly associated with a faster rate of
ADPKD progression, each cited in ten studies (Table 3). A
wide range of prognostic indicators (a total of 26) were
reported, many of which were only reported by one study,
indicating a lack of consensus in the literature on the
parameters implicated in ADPKD progression.
Seventeen publications from the Consortium for Radio-
logic Imaging Studies in Polycystic Kidney Disease
(CRISP) study were identified by the systematic review
[15–17, 43–56]. CRISP is a prospective, long-term obser-
vational study, including 241 ADPKD patients with nor-
mal renal function who were considered at high risk of
renal insufficiency. The study was initiated to increase the
knowledge and understanding of ADPKD prognosis by es-
tablishing reliable measures of disease progression [2].
Patients were diagnosed due to a positive family history
(asymptomatic family screening) or based on signs and
symptoms related to the disease. The study includes
patients with defined hypertension diagnosed before the
age of 35 years; ADPKD diagnosed in utero or in the first
year of life; 24-h urinary protein excretion greater than
300 mg/day; or an episode of gross haematuria in men
before the age of 30 years (CRISP I population) [57]. A
range of measurements have thus far been reported, and
patients have been stratified by several different criteria
across the CRISP publications, demonstrating the rele-
vance of a number of prognostic factors, such as gender
and age at diagnosis (Table 2). CRISP has identified the
importance of TKV as a key prognostic indicator, particu-
larly in the early stages of ADPKD where significant renal
enlargement can occur prior to the loss of renal function
[2, 46]. The CRISP study is ongoing, with 203 patients
having been re-enrolled in CRISP II from July 2007 [15].
Patients were stratified by rate of ADPKD progression,
and groups defined as fast or slow progressors (large or
small annual decline in GFR, respectively), in four obser-
vational studies (Additional file 3) [56, 58–60]. Although
this concept is important in the clinical setting, there is
no definitive conclusion in the literature as to how the
rate of progression should be measured or stratified.
Across the four studies, a range of prognostic indicators
were reported, including initial GFR, high blood pres-
sure, age at diagnosis and TKV at a given time point.
Disease severity was correlated with HRQoL in a sin-
gle study [11]. In general, for patients with a lower GFR,
Short Form-36 health survey scores were lower, indicat-
ing reduced HRQoL [11].
A research group in Brest, France, conducted an obser-
vational study assessing 26 clinical, biological and genetic
Fig. 1 PRISMA diagram of the systematic review. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses
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Table 2 Summary of observational studies that identified prognostic indicators for ADPKD
Publication(s) Objectives Study details Methodology for the assessment of disease
progression and identification of prognostic
indicators
Results and conclusions
Schrier, 2003 [40] To assess the effect of increased
research, identification of
prognostic factors, and a higher
number of anti-hypertensive med-
ications on ADPKD progression
An observational study was conducted over
two time periods, 255 patients from 1985
to 1992 (38 % male, age 37.5 ± 10 years,
mean renal volume 701 cm3) and 258
patients from 1992 to 2001 (31 % male, age
37.5 ± 10 years, mean renal volume
704.5 cm3)
Regression analyses were performed for all
patients to identify factors correlated with
progression to ESRD, defined as dialysis or
renal transplant
Age (P < 0.0001), renal volume (P < 0.0001),
MAP (P = 0.0026) and UPE (P = 0.0051), but
not gender, correlated with progression to
ESRD
CRISP: Grantham, 2006;
Torres, 2007, 2010, 2011;
Harris, 2006; Irazabal,
2012; Marier, 2013 [15–
17, 46, 48, 49, 55]
To identify markers of ADPKD
disease progression
A prospective, long-term observational
study of 241 ADPKD patients with normal
renal function who were considered at high
risk of renal insufficiency
Correlations between BL characteristics
(including age, gender, BMI, hypertension,
MAP, TKV, TCV, RBF, RVR, GFR, serum uric
acid, Cho, 24-hour urine volume, UNaE,
UAE, and estimated protein intake) and
ΔTKV or ΔeGFR were assessed over 3, 6 or
8 years
Factors that predict ΔTKV:
• BL TKV (P < 0.001)
• BL RBF, UNaE, HDL-c, and age at BL (P ≤
0.05)
• Male gender (P = 0.0163)
• UAE (when BL TKV was excluded, P ≤
0.005)
• There was no significant difference in
ΔTKV or ΔTCV between patients with PKD1
and PKD2 mutations (P = 0.24 and 0.79,
respectively)
Factors that predict ΔGFR:
• TKV (P < 0.02, 6 years’ follow-up). TKV for
patients with BL TKV > 1500 mL (P < 0.001),
but not for BL TKV < 750 mL (P = 0.063) or
750–1500 mL (P = 0.57, after 3 years of
follow up)
• Age (when BL GFR was excluded, P ≤ 0.02)
• SCr, BUN (both P≤ 0.001)
• BL GFR, RBF and UNaE (P ≤ 0.02)
• UAE, BSA and 24-h urine osmolarity (when
BL GFR was excluded, P ≤ 0.02)
Kistler, 2009 [92] To assess the reliability of TKV MRI
imaging over 6 months with the
aim of using such timescales in
studies of potential treatments
A prospective study of 100 young patients
with ADPKD (63 % male, mean age 31.2 ±
6.4 years, 97 % had family history of
ADPKD) with preserved GFR
Correlations between % change in TKV and
clinical and demographical parameters (not
specified) were calculated to identify
prognostic indicators
Higher ΔTKV were observed in males
(P = 0.339) and in patients with albuminuria
(P = 0.005)
Boertien, 2010, 2012 [93,
94]
To study the correlation between
endogenous vasopressin
concentration using plasma
copeptin as a marker, and renal
function
A review of data from a trial investigating
the effect of an ACEI on progression of
ADPKD (no treatment effect reported). Data
were reviewed for 79 patients (43 % male,
age 36.8 ± 10.1 years, GFR 96.8 ± 18.2 mL/
min/1.73 m2) over a median of 11.2 years
ΔeGFR was used as a measure of renal
function
Higher baseline copeptin was associated
with a faster ΔeGFR (P < 0.01). This
association was independent of age,













Table 2 Summary of observational studies that identified prognostic indicators for ADPKD (Continued)
Azurmendi, 2011 [23] To investigate albuminuria,
measured by urinary Alb/Cr, as a
predictor of disease progression
32 patients with ADPKD (mean age 26 ±
1 years) were observed over 30 ± 1 months
Yearly change in TKV, urinary MCP1 and
eGFR were used as measures of renal
function
In patients with high urinary Alb/Cr, yearly
change in both TKV and urinary MCP1, but
not eGFR, were increased compared with
patients with normal urinary Alb/Cr
(P < 0.05)
Griveas, 2012 [58] To identify patients with ADPKD
who progressed and those who
did not
A retrospective review of 120 patients (39 %
male, age 36.7 ± 12.7 years) was conducted
with a median follow-up of 52 months
Correlations were made between annual
change in eGFR and the following BL
characteristics:
Higher BL eGFR was associated with a faster
ΔeGFR (P = 0.04). Correlations between











indicators of disease progression
in Japanese patients with ADPKD
A mutation search was conducted in the
coding and flanking regions of PKD1/2 from
180 patients from 161 unrelated families
Multiple linear regression analyses were
conducted to assess the correlations
between eGFR decline and gene mutations,
plasma arginine vasopressin, and urine
osmolarity
• Patients with PDK1 mutations had
significantly faster ΔeGFR than patients with
PDK2 mutations (P < 0.01)
• There was no association between ΔeGFR
and mutation type or position
• Lower urine osmolarity was found to
correlate with ΔeGFR (significance not
reported)
• Plasma arginine vasopressin was
significantly associated with ΔeGFR in
patients with PDK1 mutations (P = 0.018)
Panizo, 2012 [60] To analyse factors influencing
ADPKD disease progression
A retrospective observational study was
conducted in 101 patients with ADPKD
(mean age 43 ± 17.3 years, 43.6 % male,
median follow-up 69 months, mean kidney
size 14.8 ± 2.9 cm, mean eGFR 74.5 ±
32.0 mL/min/1.73 m2)
The following data were collected as
potential prognostic markers using eGFR
reduction as an indicator of renal function
decline:
• SBP, DBP, uric acid, total and LDL-c, Cr,
microalbuminuria and kidney size were
significantly associated with ΔeGFR
(P≤ 0.05)
• Kidney size • Younger age at diagnosis was also
associated with rapid ΔeGFR (P = 0.010)

























CRISP: Warner, 2012 [56] To assess the association between
CPSA and decline in eGFR to
determine whether this is a better
indicator of ADPKD progression
than TKV
Patients were randomly selected from the
CRISP cohort: 10 rapid progressors, 10 slow
progressors, and 4 atypical cases with large
TKV and a small number of cysts at
baselinea
• When the atypical cases were excluded
from the analysis, BL lnCPSA and lnTKV
correlated equally well with ΔeGFR over
6 years (P = 0.0003)
• When atypical cases were included,
baseline lnCPSA correlated better than
lnTKV with ΔeGFR (P < 0.0001 and
P = 0.0008, respectively)
Hwang, 2013 [97] To investigate the association
between asymptomatic pyuria
and the development of UTIs and
the deterioration of renal function
Retrospective case control study of 256
patients with ADPKD (52 % male, mean age
48.1 ± 12.8 years, mean eGFR 91.1 ±
29.2 mL/min/1.73 m2) in South Korea
observed over 1 year
ΔGFR was used as a measure of renal
function
Patients with chronic asymptomatic pyuria,
who were predominantly female (58.5 %)
exhibited a significantly faster ΔGFR
(P = 0.01) than patients without pyuria or
with transient pyuria
Lacquaniti, 2013 [98] To quantify the predictive
potential of apelin (marker of
vasopressin) and copeptin
(antagonist of vasopressin
signalling) in ADPKD disease
progression
A prospective observational study of 52
patients with ADPKD (60 % male, mean age
43 ± 10 years, mean TKV 1057.3 ± 417.9 mL,
mean mGFR 47.7 ± 35.6 mL/min/1.73 m2)
and 50 matched healthy control patients
(50 % male, mean age 40.3 ± 9.6 years,
mean mGFR 116.6 ± 17 mL/min/1.73 m2)
were followed for 24 months
Renal function was assessed by
combination of ΔmGFR and ΔTKV (>5 % per
year)
Concentrations of apelin < 68.5 pg/mL
(P = 0.0002) and copeptin > 9.5 pmol/L
(P = 0.02) were each associated with a faster
decline in renal function
Ozkok, 2013 [59] To investigate the importance of
clinical characteristics and
biochemical data on disease
progression
323 patients with ADPKD (46 % male, mean
age 53 ± 15 years) were followed for a
mean of 100 ± 38 months
In Cox regression analysis, the following
factors were assessed as potential
predictors of ΔGFR:
Age, hypertension, hernia, proteinuria, and
urinary stone were significantly associated





• History of hypertension
• Abdominal wall hernia
• Hepatic cyst


















Table 2 Summary of observational studies that identified prognostic indicators for ADPKD (Continued)
Spithoven, 2013 [99] To measure CCr(TS) in patients
with ADPKD compared with
healthy adults
A case control study of 125 patients with
ADPKD (56 % male, mean age 40.4 ±
10.8 years, mean TKV 1470 mL, mean mGFR
77.7 ± 30.1 mL/min/1.73 m2) and 215
healthy controls (48 % male, mean age
53.1 ± 10.3 years, mean eGFR 97.7 ±
17.0 mL/min/1.73 m2)
CCr(TS) was used as a measure of renal
function
• CCr(TS) was significantly higher for
patients with ADPKD than for controls
(P < 0.001), which may be due to cyst
formation
• In patients with ADPKD, CCr(TS) correlated
with BMI (P = 0.003), BL mGFR (P = 0.03) and
age (P = 0.07), but was not associated with
TKV, female sex, filtration fraction, serum
albumin, albuminuria (all P > 0.1)
Thong & Ong, 2013
[100]
To analyse the natural history of
ADPKD progression
A retrospective study of 210 patients with
ADPKD (48.6 % male, mean age 45.6 ±
16.2 years)
Regression analyses were performed to
identify risk factors for ΔeGFR for 55
patients who had eGFR and kidney length
measurements recorded over 5 years
ΔeGFR was significantly associated with age
at diagnosis and with mean kidney length
(both P < 0.05). Gender, hypertension,
haematuria, proteinuria, UTIs, and liver cysts
were not significantly associated with renal
function decline
Chen, 2014 [14] To identify parameters that predict
cyst growth and decline in renal
function
A prospective, longitudinal observational
study was performed in 541 Chinese
patients with ADPKD and eGFR ≥30 mL/
min/1.73 m2 (54 % male, mean age 39.7 ±
12.1 years, eGFR 100.4 ± 20.1 mL/min/
1.73 m3) over a median follow-up of 14.3 ±
10.6 months
Analyses were performed for 279 patients
with measurements for all variables of the
correlation between yearly change in eGFR
or yearly % growth in TKV and:
The following parameters correlated with
yearly eGFR:
• Age
• Age (P = 0.016)
• Sex
• History of hypertension (P = 0.056)
• Observation time
• Use of anti-hypertensive drugs (P = 0.102)
• History of hypertension
• BL eGFR (P = 0.290)
• Use of anti-hypertensive drugs
• Log10 Pr/Cr (P < 0.001)
• BP
• Log10 BL TKV (P < 0.001)
• Macrohaematuria




• BL thrombocyte count
The following parameters correlated
significantly with yearly TKV:
• Age (P < 0.001)
• Male sex (P = 0.023)
• Observation time (P = 0.072)
• Use of anti-hypertensive drugs (P = 0.015)
• DBP (P = 0.041)
• BL eGFR (P = 0.173)
• Log10 Pr/Cr (P = 0.050)
• Log10 BL TKV (P = 0.092)
• BL thrombocyte count (P = 0.042)
Higashihara, 2014 [101] To assess the relationship
between TKV and kidney function
(measured by eGFR)
An observational study of 64 patients with
ADPKD who completed ≥3 measurements
and did not have any clinical conditions
TKV, GFR, SCr, Cr clearance, UPE, and BP
were measured over 5 years
• TKV, height-adjusted TKV, BSA-adjusted
TKV and log-TKV significantly correlated













Table 2 Summary of observational studies that identified prognostic indicators for ADPKD (Continued)
affecting kidney volume (33 % male, mean
age 47.0 ± 14.1 years, mean TKV 1681.1 ±
1001.1 mL, mean eGFR 60.2 ± 27.38 mL/
min/1.73 m2)
• BL TKV, age, and final eGFR were
significantly associated with the yearly
change in eGFR (P = 0.0349, P < 0.001,
P = 0.0011, respectively), but the
relationship between BL eGFR and the
yearly change in eGFR was not significant
(P = 0.4007)
• Although there was no significant
correlation between age and the TKV
parameters investigated (P > 0.1), there was a
significant relationship between age and
both the yearly % change in TKV and change
in log-TKV (P < 0.01)
• There was a significant correlation
between BL and final TKV and the yearly
change in TKV (both P < 0.001)
ACEI angiotensin-converting enzyme inhibitor, ADPKD autosomal dominant polycystic kidney disease, Alb/Cr albumin/creatinine ratio, ARB angiotensin receptor blocker, BL baseline, BMI body mass index, BP blood
pressure, BSA body surface area, BUN blood urea nitrogen, CCr(TS) tubular secretion of creatinine, Cho cholesterol, CPSA cyst parenchyma surface area, Cr creatinine, CRISP consortium for radiologic imaging studies in
polycystic kidney disease, DBP diastolic blood pressure, ΔeGFR rate of decline in estimated glomerular filtration rate, ΔTCV rate of increase in total cyst volume, ΔTKV rate of increase in total kidney volume, eGFR
estimated glomerular filtration rate, GFR glomerular filtration rate, Hb haemoglobin, HDL-c high density lipoprotein cholesterol, LDL-c low density lipoprotein cholesterol, MAP mean arterial pressure, MCP1 monocyte
chemoattractant protein-1, mGFR measured glomerular filtration rate, MRI magnetic resonance imaging, Pr/Cr protein/creatinine ratio, RBF renal blood flow, RVR renal vascular resistance, SBP systolic blood pressure, SCr
serum creatinine, TCV total cyst volume, TKV total kidney volume, UAE urine albumin excretion, UNaE urine sodium excretion, UPE urine protein excretion, UTI urinary tract infection













variables (not specified) for use in a prognostic model.
The model was based on data from 1017 patients with
ADPKD, and was tested in a sub-population of 255 pa-
tients who had either reached ESRD or were aged over
60 years [41]. The presence of hypertension along with at
least one urologic complication, or the presence of a
truncating PKD1 mutation was reported to be associated
with poorest renal outcome [41].
Clinical trials
The 33 clinical trial publications were reviewed to en-
sure the same data were not extracted from multiple
Table 3 Publications that reported a correlation between prognostic indicators and change in renal function or volume
Prognostic indicator Number of publications
reporting prognostic
indicator
Publications reporting a significant association
between prognostic indicator and rate of decrease
in renal function (GFR)
Publications reporting a significant
association between prognostic
indicator and rate of increase in renal
volume
Age e.g. age at diagnosis
(years)
10 Higashihara, 2014 [101], Chen, 2014 [14], Schrier 2003
[40], Thong, 2013 [100]a, Torres, 2007 [16]a,b, Panizo,





Baseline TKV e.g. log10
baseline TKV (cm3)
10 Higashihara, 2014 [101], Chen, 2014 [14]d, Grantham,
2006 [46]e, Schrier, 2003 [40]f, Warner, 2012 [56],
Panizo, 2012 [60]g, Lacquaniti, 2013 [98]h, Marier,




Torres, 2007, 2011 [15, 16]
Baseline GFR (either
estimated or measured)
6 Higashihara, 2014 [101]j, Chen, 2014 [14], Griveas,





5 Schrier, 2003 [40], Torres, 2007 [16]k, Ozkok, 2013
[59], Panizo, 2012 [60]l
Kistler, 2009 [92]
Torres, 2007 [16]b
Blood pressure e.g. mean
arterial pressure (mmHg)
4 Schrier, 2003 [40]m, Panizo, 2012 [60]n, Chen, 2014
[14]o,p, Ozkok, 2013 [59]o
Chen, 2014 [14]q





3 Torres, 2007 [16] Torres, 2007, 2011 [15, 16]
Irazabal, 2012 [48]
Protein/creatinine ratio 2 Azurmendi, 2011 [23]r Chen, 2014 [14]
Chen, 2014 [14] Azurmendi, 2011 [23]s
PKD1 genotype 2 Kurashige, 2012, 2013 [95, 96] None
Cholesterol e.g. serum
HDL-c (mg/dL)
1 None Torres, 2011 [15]s
Othert,u 14 Chen, 2014 [14], Grantham, 2006 [46], Hwang, 2013
[97], Panizo, 2012 [60], Ozkok, 2013 [59], Warner,
2012 [56], Kurashige, 2013 [96], Spithoven, 2013
[99]c, Lacquaniti, 2013 [98]h, Torres, 2007, 2010, 2011
[15, 16, 55]b, Boertien, 2010, 2012 [93, 94]
Chen, 2014 [14]
Publications of the same study have been grouped to prevent double-counting of patients
ADH antidiuretic hormone, ΔeGFR rate of decline in estimated glomerular filtration rate, eGFR estimated glomerular filtration rate, GFR glomerular filtration rate,
HDL high density lipoprotein, HDL-c high density lipoprotein cholesterol, MCP1 monocyte chemoattractant protein-1, mGFR measured glomerular filtration rate,
TKV total kidney volume
aYounger age at diagnosis bwhen baseline GFR excluded from regression analyses crenal function measured by tubular secretion of creatinine dlog10 baseline TKV
correlated with annual % growth in TKV ebaseline TKV >1500 mL frenal volume; gkidney size; hrenal function assessed by combination of decrease in mGFR and
increase in TKV ibaseline and final TKV jfinal eGFR (P = 0.001) but not baseline eGFR (P = 0.401) significantly correlated with annual ΔeGFR kalbuminuria;
lmicroalbuminuria; mmean arterial pressure ndiastolic and systolic blood pressure ohistory of hypertension pintake of hypertensive drugs qdiastolic blood pressure
and antihypertensive drug intake rhigh urinary albumin/creatinine ratio sserum HDL tother prognostic indicators in studies assessing disease progression by
measures of renal function include: baseline creatinine, body mass index, body surface area, chronic asymptomatic pyuria, cholesterol, cyst parenchyma surface
area, copeptin levels, MCP-1, plasma ADH in PKD1 patients, presence of hernia, renal blood flow, thrombocyte count, uric acid, urinary stone and urine osmolality
uother prognostic indicators in studies assessing disease progression by measures of renal volume include: apelin levels, copeptin levels, renal blood flow, and
thrombocyte count
Woon et al. BMC Nephrology    Page 10 of 16
reports of the same study. Of these 33, 24 unique re-
ports were identified. The trials assessed the efficacy of
three main drug types to slow the progression of
ADPKD:
 Mammalian target of rapamycin inhibitors, e.g.
sirolimus, everolimus and tacrolimus [61–67].
 Somatostatin analogues, e.g. somatostatin, lanreotide
and octreotide [68–73].
 The vasopressin v2 receptor antagonist, tolvaptan
[74–80].
Further drugs were:
 Eicosapentaenoic acid, an anti-inflammatory omega-
3 fatty acid [81].
 Pravastatin, a statin [82].
 Anti-hypertensives, e.g. angiotensin-converting
enzyme inhibitors (ACEIs) (enalapril or ramipril)
[83, 84] or the beta-blocker metoprolol [84].
In the clinical trials assessing treatments to halt or
slow the development of ADPKD, efficacy was assessed
using measures of disease progression. Change in TKV
or renal function, measured by GFR or serum creatinine
concentration, were the most commonly used primary
endpoints in the identified trials.
Other primary endpoints considered in studies of
disease-modifying interventions in patients with ADPKD
included change in liver volume, change in TCV and
change in urinary fatty acid-binding protein. The num-
ber of different primary endpoints used in the identified
trials demonstrated inconsistencies in the measurement
of efficacy due to the paucity of data on the progression
of ADPKD.
In the 21 publications that reported data at multiple
time points, the most frequently reported outcomes were
TKV (14 reports, 66.7 %), eGFR (12 reports, 57.1 %),
serum creatinine (7 reports, 33.3 %) and systolic blood
pressure (9 reports, 42.9 %). Of these, 12 studies reported
data at two time points and eight studies reported data at
three or four time points. Data were recorded at baseline
and after 6 months in six studies [62, 65, 68, 71–73], at
baseline and after 12 months in one study [70], at baseline
and after 24 months in three studies [61, 66, 82], and at
baseline and after 36 months in two studies [83, 84].
Due to the short study duration and lack of suitable
sub-analyses or patient level data, disease progression
data from these trials were not appropriate for the as-
sessment of the prognostic potential of the variables
measured at baseline.
Hypertension was targeted as a manifestation of
ADPKD in the Halt Progression of Polycystic Kidney
Disease (HALT-PKD) study, a clinical trial studying the
intensive blockade of the renin-angiotensin system with
combination ACEIs and angiotensin receptor blockers
(ARBs). The study aimed to test the hypothesis that rigor-
ous blood pressure control was more effective in slowing
progression of renal disease in early ADPKD than moder-
ate blood pressure control, by comparing the combination
treatment to ACEI monotherapy alone. The primary end-
point was annual change in TKV, which was lower with
rigorous blood pressure control than with moderate blood
pressure control (P = 0.006). The rate of change in GFR
was similar for the two treatment groups [85, 86].
Reviews
The 61 non-systematic and systematic reviews and meta-
analyses identified were mainly focussed around new and
potential treatment options, as well as reviews of the
genetics, pathophysiology and manifestations of the dis-
ease. In general, the identified reviews acknowledged and
discussed a range of different prognostic indicators, but
did not provide conclusive agreement on these factors.
Discussion
Our review demonstrated that, as a result of the exten-
sive clinical variability associated with ADPKD, a range
of biological, genetic and clinical characteristics have
been reported in the published literature for both the
prediction and measurement of ADPKD progression.
Currently, therapeutic options for ADPKD focus on
management of the symptoms and complications of the
disease since there is no available treatment to slow
ADPKD progression. Stratification of patients based on
their predicted rate of progression could improve symptom
management. The uncertainty surrounding the clinical pro-
gression of the disease has also contributed to a paucity of
clinical trials investigating potential interventions.
Due to the variability in the rate of ADPKD progres-
sion and the length of time taken for patients to reach
ESRD, progression to ESRD is a poor candidate endpoint
for use in clinical trials. Instead, predictors/indicators of
time to disease progression have been used to assess the
efficacy of treatments; however, a variety of different
endpoints have been employed. This has led to problems
in demonstrating conclusive efficacy and in comparing
treatments across trials. As a result, no consensus has
been reached regarding the optimal endpoints to assess
the progression of ADPKD and the efficacy of potential
therapies. A range of observational studies have attempted
to address this, but there is inconsistency in the parame-
ters reported and in the assessment of disease progression.
Studies evaluating ADPKD have generally been con-
ducted in relatively small study populations, because the
slow rate of progression and the lengthy period during
which GFR is within the normal range limits the size
of the population available for analysis. The CRISP
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observational study is a rich data source that has
assessed several prognostic indicators in a relatively
large cohort of patients with ADPKD, selected in
order to study the clinical and radiological features of
perceived fast progressors over a long follow-up
period (6 years) [15, 46]. To assess the relationship be-
tween baseline TKV and renal growth over time, the co-
hort was stratified; a greater baseline TKV at a younger
age was associated with a more rapid increase in TKV
[46].
CRISP also illustrated that, although GFR does not
typically change until the fourth or fifth decade of life,
renal enlargement progresses significantly in the early
stages of the disease, identifying large TKV as a key indi-
cator of early disease progression [2, 46]. This provides
evidence that early treatment may be important to slow
or halt the progression of ADPKD before cyst develop-
ment causes irreversible damage [46]. Other prognostic
indicators of relevance included hypertension, gender
and age at diagnosis, some of which correlate with those
identified by other studies [2]. It is anticipated that these
prognostic indicators will be used in the future evalu-
ation of treatments that aim to slow the progression of
ADPKD and will lead to improvement and standardisa-
tion of trial design [2]. However, the CRISP study also
has limitations in that, compared with the general
ADPKD population, CRISP enrolled a younger cohort
with well-preserved renal function. Further analyses are
required to validate these findings in the wider ADPKD
population with a broader range of renal function and
volumes.
Since the searches were conducted, three abstracts from
the PKD Outcomes Consortium (PKDOC) have been pre-
sented [87–89]. The PKDOC dataset is the largest ADPKD
dataset currently available and includes data from CRISP in
addition to other study populations from the Mayo Clinic,
Emory University and the University of Colorado [89].
These abstracts validate the use of TKV as an important
prognostic indicator, identifying baseline TKV and baseline
eGFR as prognostic biomarkers for both eGFR decline and
progression to ESRD.
Our systematic review has identified a wide range of
prognostic indicators that have been proposed or assessed
in observational studies and clinical trials, but there is cur-
rently no agreement within the literature. The absence of
long term patient level data from the identified clinical tri-
als prevented correlations between variables measured at
baseline and the rate of disease progression. In observa-
tional studies, age and TKV at baseline were the two fac-
tors most commonly cited as significantly associated with
a faster rate of ADPKD progression. However, further re-
search is required to validate these factors as true indica-
tors of disease progression. Reported prognostic indicators
may be complications of ADPKD that are exacerbated by
disease progression, rather than factors driving the under-
lying progression of the disease, or may exhibit a cause-
effect association, in which they both exacerbate and are
worsened by the progression of the disease.
The specific genotype of patients with ADPKD has
also generated interest as a potential indicator of disease
progression rate. Although it is generally agreed in the
literature that patients with PKD1 mutations have larger
kidneys and worse renal function compared to patients
with PKD2 mutations, few papers report the use of GFR
and/or TKV to measure disease progression in patients
stratified by genotype. Therefore, despite the large num-
ber of potential prognostic indicators identified, there
may be an interaction between some, possibly enabling
the collapse of several prognostic indicators into fewer
key factors that are most informative. The two most
commonly reported prognostic indicators identified by
this review were age and TKV at baseline, which may
encapsulate other factors such as PKD gene mutation,
renal blood flow and baseline GFR.
Due to inter-patient heterogeneity in renal size and gen-
etic profile, current diagnostic practices based on renal
ultrasound and family histories are suboptimal. Recently,
urinary proteomic and microRNA biomarkers have been
identified that could be used as a non-invasive method of
diagnosing patients with ADPKD [90, 91]. Long-term
studies are ongoing to determine whether such markers
also serve as prognostic indicators in ADPKD [90]. How-
ever, initial results are promising as a correlation was
observed between the urinary peptide profile and height-
adjusted TKV in patients with ADPKD [91].
The identification of prognostic indicators is of great
importance in the drive to improve the management of
ADPKD, as a better understanding of patients’ clinical
prognosis may lead to improved symptom management
that can be tailored to individuals, depending on their pre-
dicted rate of progression. This knowledge will also aid the
stratification and selection of patients for disease-modifying
treatments, as well as providing a basis for improved
clinical trial design with standard endpoints to evaluate
and compare treatments. A more thorough understand-
ing of the natural history of ADPKD may be beneficial
in terms of optimising treatment. The construction of a
disease progression model to predict the progression of
ADPKD, incorporating the identified prognostic indica-
tors, could be informative for the future management of
the disease.
Conclusions
There has previously been little clinical consensus re-
garding the prognostic indicators associated with disease
progression in ADPKD, especially in the early stages of
the disease. As a result, ADPKD progression has been
assessed using a wide range of patient and clinical
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characteristics. A systematic review of the literature has
identified age and TKV as the two factors most com-
monly cited as significantly associated with a faster rate
of ADPKD progression, particularly in the early stages of
the disease. By identifying these prognostic indicators it
is hoped there is an opportunity to improve trial design
and conduct further research, including a predictive
model of ADPKD natural history, in order to provide
clinicians with a clearer understanding of factors influ-
encing disease progression, thereby helping to optimise
patient care.
Additional files
Additional file 1: PRISMA 2009 checklist. A checklist of items to be
reported in systematic reviews and meta-analyses (DOCX 18 kb)
Additional file 2: General search string. General search string used to
interrogate databases and identify potential studies of interest.
(DOCX 17 kb)
Additional file 3: Definitions of fast and slow progression.
Definitions of fast and slow progression of ADPKD used in observational
studies. (DOCX 18 kb)
Abbreviations
ACEI: Angiotensin-converting enzyme inhibitor; ADPKD: Autosomal dominant
polycystic kidney disease; ARB: Angiotensin receptor blocker; CDSR: Cochrane
database of systematic reviews; CENTRAL: Cochrane central register of
controlled trials; CKD-EPI: Chronic kidney disease epidemiology collaboration;
CRISP: Consortium for radiologic imaging studies in polycystic kidney
disease; eGFR: Estimated glomerular filtration rate; ESRD: End stage renal
disease; GFR: Glomerular filtration rate; HALT-PKD: Halt progression of
polycystic kidney disease; HEED: Health economic evaluations database;
HRQoL: Health-related quality of life; MDRD: Modification of diet in renal
disease; mGFR: Measured glomerular filtration rate; MRI: Magnetic resonance
imaging; NHS EED: NHS economic evaluation database; PKD: Polycystic
kidney disease; PKDOC: Polycystic kidney disease outcomes consortium;
PRISMA: Preferred reporting items for systematic reviews and meta-analyses;
TCV: Total cyst volume; TKV: Total kidney volume; TRV: Total renal volume.
Competing interests
Otsuka Pharmaceutical Europe Ltd, who funded this review and employ KOR
and PR, produce tolvaptan, which is now approved for use in Europe,
Canada and Japan.
Authors’ contributions
CW and ABB participated in the study design, database searching, filtering of
records, data analysis and preparation of the article. KOR and PR participated
in the study design, data analysis and preparation of the article. All authors
read and approved the final manuscript.
Acknowledgements
The authors would like to thank ACM Ong, B Ørskov, R Sandford and G Walz
for their advice and collaboration. The authors also acknowledge J
Moorhouse (Double Helix Consulting) for assistance with the filtering of
records and revision of the manuscript. This study was funded by Otsuka
Pharmaceutical Europe Ltd.
Author details
1Double Helix Consulting, Complete House, Macclesfield, Cheshire, UK.
2Otsuka Pharmaceutical Europe Ltd, Wexham, UK.
Received: 29 January 2015 Accepted: 20 July 2015
References
1. Nahm AM, Henriquez DE, Ritz E. Renal cystic disease (ADPKD and ARPKD).
Nephrol Dial Transplant. 2002;17:311–4.
2. Chapman AB. Approaches to testing new treatments in autosomal
dominant polycystic kidney disease: insights from the CRISP and HALT-PKD
studies. Clin J Am Soc Nephrol. 2008;3:1197–204.
3. Luciano RL, Dahl NK. Extra-renal manifestations of autosomal dominant
polycystic kidney disease (ADPKD): considerations for routine screening and
management. Nephrol Dial Transplant. 2014;29:247–54.
4. Chapal M, Debout A, Dufay A, Salomon R, Roussey G, Burtey S, et al. Kidney
and liver transplantation in patients with autosomal recessive polycystic
kidney disease: a multicentric study. Nephrol Dial Transplant.
2012;27:2083–8.
5. Heidland A, Bahner U, Deetjen A, Gotz R, Heidbreder E, Schafer R, et al.
Mass-screening for early detection of renal disease: benefits and limitations
of self-testing for proteinuria. J Nephrol. 2009;22:249–54.
6. Neumann HP, Jilg C, Bacher J, Nabulsi Z, Malinoc A, Hummel B, et al.
Epidemiology of autosomal-dominant polycystic kidney disease: an
in-depth clinical study for south-western Germany. Nephrol Dial Transplant.
2013;28:1472–87.
7. Patch C, Charlton J, Roderick PJ, Gulliford MC. Use of antihypertensive
medications and mortality of patients with autosomal dominant polycystic
kidney disease: a population-based study. Am J Kidney Dis.
2011;57:856–62.
8. Torres VE, Rossetti S, Harris PC. Update on autosomal dominant polycystic
kidney disease. Minerva Med. 2007;98:669–91.
9. Shaw C, Simms RJ, Pitcher D, Sandford R. Epidemiology of patients in
England and Wales with autosomal dominant polycystic kidney disease and
end-stage renal failure. Nephrol Dial Transplant. 2014;29:1910–8.
10. Spithoven EM, Kramer A, Meijer E, Orskov B, Wanner C, Caskey F, et al.
Analysis of data from the ERA-EDTA Registry indicates that conventional
treatments for chronic kidney disease do not reduce the need for renal
replacement therapy in autosomal dominant polycystic kidney disease.
Kidney Int. 2014;86:1244–52.
11. Miskulin DC, Abebe KZ, Chapman AB, Perrone RD, Steinman TI, Torres VE,
et al. Health-related quality of life in patients with autosomal dominant
polycystic kidney disease and CKD stages 1–4: a cross-sectional study.
Am J Kidney Dis. 2014;63:214–26.
12. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. Ann Intern
Med. 2009;151:264–9. W64.
13. Higgins JPT, Green S. Cochrane handbook for systematic reviews of
interventions Version 5.1.0. The Cochrane Collaboration. 2011.
http://www.cochrane-handbook.org. Accessed 15 Jan 15 A.D.
14. Chen D, Ma Y, Wang X, Yu S, Li L, Dai B, et al. Clinical characteristics and
disease predictors of a large Chinese cohort of patients with autosomal
dominant polycystic kidney disease. PLoS One. 2014;9, e92232.
15. Torres VE, Grantham JJ, Chapman AB, Mrug M, Bae KT, King BF, et al.
Potentially modifiable factors affecting the progression of autosomal
dominant polycystic kidney disease. Clin J Am Soc Nephrol.
2011;6:640–7.
16. Torres VE, King BF, Chapman AB, Brummer ME, Bae KT, Glockner JF, et al.
Magnetic resonance measurements of renal blood flow and disease
progression in autosomal dominant polycystic kidney disease. Clin J Am
Soc Nephrol. 2007;2:112–20.
17. Harris PC, Bae KT, Rossetti S, Torres VE, Grantham JJ, Chapman AB, et al. Cyst
number but not the rate of cystic growth is associated with the mutated
gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol.
2006;17:3013–9.
18. Irazabal-Mira MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG, et al.
Short-term effects of tolvaptan on renal function and volume in patients
with autosomal dominant polycystic kidney disease (ADPKD). J Am Soc
Nephrol. 2010;21 Suppl:528A–9. abstract F-PO1824.
19. Ulusoy S, Ozkan G, Kosucu P, Kaynar K, Eyuboglu I. A comparison of the
effects of losartan and ramipril on blood pressure, renal volume and
progression in polycystic kidney disease: A 5-Year follow-up. Hippokratia.
2012;16:143–8.
20. Peces R, Cuesta-Lopez E, Peces C, Perez-Duenas V, Vega-Cabrera C, Selgas R.
Octreotide reduces hepatic, renal and breast cystic volume in
autosomal-dominant polycystic kidney disease. Int U Nephrol.
2011;43:565–9.
Woon et al. BMC Nephrology    Page 13 of 16
21. Rim H, Jung GS, Jung YS. Transcatheter arterial embolization using ethanol
in a dialysis patient for contracting enlarged polycystic kidneys. Korean J
Radiol. 2010;11:574–8.
22. Ulusoy S, Ozkan G, Orem C, Kaynar K, Kosucu P, Kiris A. A comparison of the
effects of ramipril and losartan on blood pressure control and left ventricle
hypertrophy in patients with autosomal dominant polycystic kidney disease.
Ren Fail. 2010;32:913–7.
23. Azurmendi PJ, Fraga AR, Valdez MG, Arrizurieta E, Martin RS. Early
progression markers in autosomal dominant polycystic kidney disease. A
longitudinal study in patients with normal GFR. J Am Soc Nephrol. 2011;22
Suppl:301A. abstract TH-PO819.
24. Dicks E, Ravani P, Langman D, Davidson WS, Pei Y, Parfrey PS. Incident renal
events and risk factors in autosomal dominant polycystic kidney disease: a
population and family-based cohort followed for 22 years. Clin J Am Soc
Nephrol. 2006;1:710–7.
25. Helal I, Gitomer BY, McFann K, Yan XD, Brosnahan GM, Schrier RW. Serum
uric acid and renal disease progression in autosomal dominant polycystic
kidney disease. J Am Soc Nephrol. 2011;22 Suppl:300A. abstract TH-PO816.
26. Helal I, Gitomer BY, McFann K, Tkachenko OO, Yan XD, Schrier RW. Changing
pattern of end-stage renal disease treatment in autosomal dominant polycystic
kidney disease patient over time. J Am Soc Nephrol. 2012;23 Suppl:702A. abstract
SA-PO288.
27. Nishimura H, Ubara Y, Nakamura M, Nakanishi S, Sawa N, Hoshino J, et al. Renal
cell carcinoma in autosomal dominant polycystic kidney disease. Am J Kidney
Dis. 2009;54:165–8.
28. Orskov B, Christensen KB, Feldt-Rasmussen B, Strandgaard S. Low birth weight is
associated with earlier onset of end-stage renal disease in Danish patients with
autosomal dominant polycystic kidney disease. Kidney Int. 2012;81:919–24.
29. Orskov B, Sorensen V, Feldt-Rasmussen B, Strandgaard S. Changes in causes
of death and risk of cancer in Danish patients with autosomal dominant
polycystic kidney disease and end-stage renal disease. Nephrol Dial
Transplant. 2012;27:1607–13.
30. Spithoven EM, Kramer A, Wanner C, Jager KJ, Gansevoort RT. Incidence of
renal replacement therapy for ADPKD in Europe. J Am Soc Nephrol. 2013;24
Suppl:691A–2. abstract SA-PO279.
31. Yoo DJ, Agodoa L, Yuan CM, Abbott KC, Nee R. Risk of intracranial
hemorrhage associated with autosomal dominant polycystic kidney disease
in patients with end stage renal disease. BMC Nephrol. 2014;15:39.
32. Barua M, Cil O, Paterson AD, Wang K, He N, Dicks E, et al. Family history of
renal disease severity predicts the mutated gene in ADPKD. J Am Soc
Nephrol. 2009;20:1833–8.
33. Chang MY, Chen HM, Jenq CC, Lee SY, Chen YM, Tian YC, et al. Novel PKD1
and PKD2 mutations in Taiwanese patients with autosomal dominant
polycystic kidney disease. J Hum Genet. 2013;58:720–7.
34. Cornec-Le Gall E, Treguer L, Sawadogo T, Benarbia S, Le Meur Y. Clinical
factors predicting renal outcome in autosomal dominant polycystic kidney
disease (ADPKD): results of the GENKYST registry. Nephrol Dial Transplant.
2013;28 Suppl 1:i81–4.
35. Haynes R, Staplin N, Emberson J, Herrington G, Tomson C, Agodoa L, et al.
Evaluating the contribution of the cause of kidney disease to prognosis in
CKD: results from the study of heart and renal protection (SHARP). Am J
Kidney Dis. 2014;64:40–8.
36. Helal I, McFann K, Reed B, Yan XD, Schrier RW, Fick-Brosnahan GM. Serum
uric acid, kidney volume and progression in autosomal-dominant polycystic
kidney disease. Nephrol Dial Transplant. 2013;28:380–5.
37. Nunes ACF, Milani V, Porsch DB, Rossato LB, Mattos CB, Roisenberg I, et al.
Frequency and clinical profile of patients with polycystic kidney disease in
southern Brazil. Ren Fail. 2008;30:169–73.
38. Fary Ka E, Seck SM, Niang A, Cisse MM, Diouf B. Patterns of autosomal
dominant polycystic kidney diseases in black Africans. Saudi J Kidney Dis
Transpl. 2010;21:81–6.
39. Romao EA, Moyses Neto M, Teixeira SR, Muglia VF, Vieira-Neto OM, Dantas
M. Renal and extrarenal manifestations of autosomal dominant polycystic
kidney disease. Braz J Med Biol Res. 2006;39:533–8.
40. Schrier RW, McFann KK, Johnson AM. Epidemiological study of kidney
survival in autosomal dominant polycystic kidney disease. Kidney Int.
2003;63:678–85.
41. Cornec-Le Gall E, Hourmant M, Morin MP, Perrichot R, Charasse C, Siohan P,
et al. A new algorithm to predict renal outcome in autosomal dominant
polycystic kidney disease. J Am Soc Nephrol. 2013;24 Suppl:59A. abstract
FR-OR98.
42. Cornec-Le Gall E, Audrezet MP, Hourmant M, Morin MP, Grall-Jezequel A,
Renaudineau E, et al. PKD1 mutation type, but not the mutation location,
influences renal outcome in autosomal dominant polycystic kidney disease.
J Am Soc Nephrol. 2012;23 Suppl:49A. abstract FR-OR085.
43. Boertien WE, Meijer E, Li J, Bost JE, Struck J, Flessner MF, et al. Relationship
of copeptin, a surrogate marker for arginine vasopressin, with change in
total kidney volume and GFR decline in autosomal dominant polycystic
kidney disease: results from the CRISP cohort. Am J Kidney Dis.
2013;61:420–9.
44. Chapman AB, Bost JE, Torres VE, Mrug M, Bae KT, Grantham JJ.
Cyst-dependent renal complications in autosomal dominant polycystic
kidney disease. J Am Soc Nephrol. 2010;21 Suppl:384A. abstract
F-PO1198.
45. Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D,
et al. Kidney volume and functional outcomes in autosomal dominant
polycystic kidney disease. Clin J Am Soc Nephrol. 2012;7:479–86.
46. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King Jr
BF, et al. Volume progression in polycystic kidney disease. N Engl J Med.
2006;354:2122–30.
47. Grantham JJ, Torres VE, Chapman AB, Bae KT, Tao C, Guay-Woodford
LM, et al. Urinary monocyte chemotactic protein-1 (MCP1) predicts
progression in autosomal dominant polycystic kidney disease (ADPKD).
J Am Soc Nephrol. 2010;21 Suppl:526A. abstract F-PO1814.
48. Irazabal MV, Boertien WE, Landsittel D, Li J, Struck J, Flessner MF, et al.
Urine sodium excertion and plasma proANP as markers of disease
progression in ADPKD. J Am Soc Nephrol. 2012;23 Suppl:246A. abstract
TH-PO642.
49. Marier JF, Gosselin NH, Chittenden JT, Czerwiec FS, Levy DI, Chapman
AB, et al. Total kidney volume is a prognostic biomarker for worsening
of kidney function in patients with autosomal dominant polycystic
kidney disease. J Am Soc Nephrol. 2013;24 Suppl:686A. abstract
SA-PO259.
50. Marier JF, Mouksassi M, Jonsson F, Czerwiec FS, Levy DI, Chapman AB, et al.
Total kidney volume is a prognostic biomerker for the progression to
end-stage renal disease in patients with autosomal dominant polycystic
kidney disease over 10 years. J Am Soc Nephrol. 2013;24 Suppl:686A–7.
abstract SA-PO260.
51. Mrug M, Mrug S, Guay-Woodford LM, Torres VE, Bae KT, Harris PC, et al.
Prediction of renal function trajectories in early autosomal dominant
polycystic kidney disease. J Am Soc Nephrol. 2012;23 Suppl:66A. abstract
SA-OR005.
52. Mrug M, Mrug S, Landsittel D, Torres VE, Bae KT, Harris PC, et al. Prediction
of GFR endpoints in early autosomal dominant polycystic kidney disease.
J Am Soc Nephrol. 2013;24 Suppl:59A. abstract FR-OR97.
53. Parikh CR, Dahl NK, Chapman AB, Bost JE, Edelstein CL, Comer DM, et al.
Evaluation of urine biomarkers of kidney injury in polycystic kidney disease.
Kidney Int. 2012;81:784–90.
54. Rule AD, Torres VE, Chapman AB, Grantham JJ, Guay-Woodford LM, Bae KT,
et al. Comparison of methods for determining renal function decline in
early autosomal dominant polycystic kidney disease: the consortium of
radiologic imaging studies of polycystic kidney disease cohort. J Am Soc
Nephrol. 2006;17:854–62.
55. Torres VE, Chapman AB, King BF, Martin DR, Grantham JJ, Mrug M, et al.
Renal blood flow (RBF) is an underestimated tool to monitor the
progression of autosomal dominant polycystic kidney disease (ADPKD).
J Am Soc Nephrol. 2010;21 Suppl:527A. abstract F-PO1818.
56. Warner JD, Irazabal MV, Erickson BJ, King BF, Bae KT, Grantham JJ, et al. A
new metric to predict autosomal dominant polycystic kidney disease
(ADPKD) progression: cyst parenchyma surface area (CPSA). J Am Soc
Nephrol. 2012;23 Suppl:704A–5. abstract SA-PO296.
57. Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Bae KT,
Baumgarten DA, et al. Renal structure in early autosomal-dominant
polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging
Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int.
2003;64:1035–45.
58. Griveas I, Bishop K, World M. Adult polycystic kidney disease: who needs
hospital follow-up? Artif Organs. 2012;36:594–9.
59. Ozkok A, Akpinar TS, Tufan F, Kanitez NA, Uysal M, Guzel M, et al. Clinical
characteristics and predictors of progression of chronic kidney disease in
autosomal dominant polycystic kidney disease: a single center experience.
Clin Exp Nephrol. 2013;17:345–51.
Woon et al. BMC Nephrology    Page 14 of 16
60. Panizo N, Goicoechea M, Garcia de Vinuesa S, Arroyo D, Yuste C, Rincon A,
et al. Chronic kidney disease progression in patients with autosomal
dominant polycystic kidney disease. Nefrologia. 2012;32:197–205.
61. Mora FP, Codianni P, Liern M, Grammatico D, Vallejo G. Use of rapamycin to
reduce the pathologic kidney volume growth in autosomal polycystic
kidney disease. Pediatr Nephrol. 2013;28:1492.
62. Perico N, Antiga L, Caroli A, Ruggenenti P, Fasolini G, Cafaro M, et al.
Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol.
2010;21:1031–40.
63. Qian Q, Du H, King BF, Kumar S, Cosio FG, Torres VE. Sirolimus reduces
polycystic liver volume in ADPKD patients after renal transplantation. J Am
Soc Nephrol. 2007;18:365A.
64. Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, et al. Sirolimus and
kidney growth in autosomal dominant polycystic kidney disease. N Engl J
Med. 2010;363:820–9.
65. Soliman AR, Ismail E, Zamil S, Lotfy A. Sirolimus therapy for patients with
adult polycystic kidney disease: a pilot study. Transplant Proc.
2009;41:3639–41.
66. Stallone G, Infante B, Grandaliano G, Bristogiannis C, Macarini L,
Mezzopane D, et al. Rapamycin for treatment of type I autosomal
dominant polycystic kidney disease (RAPYD-study): a randomized,
controlled study. Nephrol Dial Transplant. 2012;27:3560–7.
67. Walz G, Budde K, Mannaa M, Nurnberger J, Wanner C, Sommerer C,
et al. Everolimus in patients with autosomal dominant polycystic kidney
disease. N Engl J Med. 2010;363:830–40.
68. Caroli A, Antiga L, Cafaro M, Fasolini G, Remuzzi A, Remuzzi G, et al.
Reducing polycystic liver volume in ADPKD: effects of somatostatin
analogue octreotide. Clin J Am Soc Nephrol. 2010;5:783–9.
69. Caroli A, Perico N, Perna A, Antiga L, Brambilla P, Pisani A, et al. Effect of
longacting somatostatin analogue on kidney and cyst growth in autosomal
dominant polycystic kidney disease (ALADIN): a randomised,
placebo-controlled, multicentre trial. Lancet. 2013;382:1485–95.
70. Chrispijn M, Nevens F, Gevers TJG, Vanslembrouck R, van Oijen MGH,
Coudyzer W, et al. The long-term outcome of patients with polycystic
liver disease treated with lanreotide. Aliment Pharmacol Ther.
2012;35:266–74.
71. Gevers TJG, Hol JC, Monshouwer R, Dekker H, Wetzels JF, Drenth JPH.
Lanreotide halts polycystic liver and kidney growth in patients with
autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2013;24
Suppl:60A–1. abstract FR-OR102.
72. Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene-Iordache B,
et al. Safety and efficacy of long-acting somatostatin treatment in
autosomal-dominant polycystic kidney disease. Kidney Int.
2005;68:206–16.
73. van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL,
Dekker HM, et al. Lanreotide reduces the volume of polycystic liver: a
randomized, double-blind, placebo-controlled trial. Hepatology.
2009;50 Suppl 4:328A.
74. Boertien WE, Meijer E, de Jong PE, Bakker SJL, Czerwiec FS, Struck J, et al.
Short-term renal hemodynamic effects of tolvaptan in subjects with
autosomal dominant polycystic kidney disease at various stages of chronic
kidney disease. Kidney Int. 2013;84:1278–86.
75. Czerwiec FS, Chapman AB, Devuyst O, Gansevoort RT, Higashihara E, Krasa
HB, et al. Clinical outcomes in ADPKD: results from the TEMPO 3:4 trial. J
Am Soc Nephrol. 2013;24 Suppl:61A. abstract FR-OR103.
76. Horie S, Higashihara E, Muto S, Nutahara K, Iino Y, Narita I, et al. Effects
of tolvaptan in ADPKD: subanalysis of Japanese patients from the
TEMPO 3:4 trial. J Am Soc Nephrol. 2013;24 Suppl:688A. abstract
SA-PO266.
77. Perrone RD, Chapman AB, Czerwiec FS, Devuyst O, Gansevoort RT,
Grantham JJ, et al. Correlation of total kidney volume and eGFR in patients
with ADPKD: results from the TEMPO 3:4 trial. J Am Soc Nephrol. 2013;24
Suppl:687A. abstract SA-PO263.
78. Torres VE, Grantham JJ, Chapman AB, Watnick T, Kedzierski K, Ouyang JJ,
et al. Phase 2 open-label study to determine safety, tolerability and efficacy
of split-dose tolvaptan in ADPKD [abstract no:SA-PO077]. J Am Soc Nephrol.
2007;18 Suppl:361A–2. abstract SA-PO077.
79. Torres VE, Chapman AB, Grantham JJ, Watnick TJ, Ouyang J, Krasa HB, et al.
TEMPO 2/4 update: changes in ADPKD total kidney volume and eGFR with
3 years of tolvaptan and after withdrawal. J Am Soc Nephrol. 2010;21
Suppl:528A. abstract F-PO1822.
80. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ,
Higashihara E, et al. Tolvaptan in patients with autosomal dominant
polycystic kidney disease. N Engl J Med. 2012;367:2407–18.
81. Higashihara E, Nutahara K, Horie S, Muto S, Hosoya T, Hanaoka K, et al. The
effect of eicosapentaenoic acid on renal function and volume in patients
with ADPKD. Nephrol Dial Transplant. 2008;23:2847–52.
82. Fassett RG, Coombes JS, Packham D, Fairley KF, Kincaid-Smith P. Effect of
pravastatin on kidney function and urinary protein excretion in
autosomal dominant polycystic kidney disease. Scand J Urol Nephrol.
2010;44:56–61.
83. van Dijk MA, Breuning MH, Duiser R, van Es LA, Westendorp RG. No effect
of enalapril on progression in autosomal dominant polycystic kidney
disease. Nephrol Dial Transplant. 2003;18:2314–20.
84. Zeltner R, Poliak R, Stiasny B, Schmieder RE, Schulze BD. Renal and cardiac
effects of antihypertensive treatment with ramipril vs metoprolol in
autosomal dominant polycystic kidney disease. Nephrol Dial Transplant.
2008;23:573–9.
85. Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, et al.
Blood pressure in early autosomal dominant polycystic kidney disease. N
Engl J Med. 2014;371:2255–66.
86. Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, et al.
Angiotensin blockade in late autosomal dominant polycystic kidney disease.
N Engl J Med. 2014;371:2267–76.
87. Perrone R, Marier JF, Mouksassi M, Romero K, Dennis EH, Miskulin D, et al.
Baseline total kidney volume is associated with worsening of kidney
function independently of baseline glomerular filtration rate in patients with
autosomal dominant polycystic kidney disease. In: Abstract 318 presented at
the National Kidney Foundation Spring Clinical Meeting, Las Vegas, Nevada,
USA, 22–26 Apr 2014. 2014.
88. Perrone R, Marier JF, Mouksassi M, Czerwiec FS, Romero K, Dennis EH, et al.
End-stage renal disease in patients with autosomal dominant polycystic
kidney disease is dependent on baseline total kidney volume and baseline
glomerular filtration rate. In: Abstract 319 presented at the National Kidney
Foundation Spring Clinical Meeting, Las Vegas, Nevada, USA,
22–26 Apr 2014. 2014.
89. Perrone R, Marier JF, Mouksassi M, Czerwiec FS, Romero K, Dennis EH, et al.
Qualification of total kidney volume as a prognostic biomarker for use in
clinical trials evaluating patients with autosomal dominant polycystic kidney
disease. In: Abstract 428 presented at the National Kidney Foundation
Spring Clinical Meeting, Las Vegas, Nevada, USA, 22–26 Apr 2014. 2014.
90. Ben-Dov IZ, Tan YC, Morozov P, Wilson PD, Rennert H, Blumenfeld JD, et al.
Urine microRNA as potential biomarkers of autosomal dominant polycystic
kidney disease progression: description of miRNA profiles at baseline. PLoS
One. 2014;9, e86856.
91. Kistler AD, Serra AL, Siwy J, Poster D, Krauer F, Torres VE, et al. Urinary
proteomic biomarkers for diagnosis and risk stratification of autosomal
dominant polycystic kidney disease: a multicentric study. PLoS One.
2013;8, e53016.
92. Kistler AD, Poster D, Krauer F, Weishaupt D, Raina S, Senn O, et al. Increases
in kidney volume in autosomal dominant polycystic kidney disease can be
detected within 6 months. Kidney Int. 2009;75:235–41.
93. Boertien WE, Meijer E, Jie L, Bost JE, Struck J, Flessner MF, et al. Copeptin, a
surrogate marker for vasopressin, is associated with disease progression in
the CRISP cohort of ADPKD patients. J Am Soc Nephrol. 2011;22 Suppl:59A.
abstract FR-OR245.
94. Boertien WE, Meijer E, Zittema D, van Dijk MA, Rabelink TJ, Breuning MH,
et al. Copeptin, a surrogate marker for vasopressin, is associated with kidney
function decline in subjects with autosomal dominant polycystic kidney
disease. Nephrol Dial Transplant. 2012;27:4131–7.
95. Kurashige M, Hanaoke K, Kawaguchi Y, Hasegawa T, Imamura M, Maeda S,
et al. Genetic and phenotypic characteristics of subjects with autosomal
dominant polycystic kidney disease in the Japanese. J Am Soc Nephrol.
2012;23 Suppl:701A. abstract SA-PO280.
96. Kurashige M, Hanaoka K, Imamura M, Kawaguchi Y, Hasegawa E, Hosoya T,
et al. A comprehensive mutation search within the PKD1/2 for Japanese
subjects with autosomal dominant polycystic kidney disease. J Am Soc
Nephrol. 2013;24 Suppl:694A. abstract SA-PO290.
97. Hwang JH, Park HC, Jeong JC, Ha Baek S, Han MY, Bang K, et al. Chronic
asymptomatic pyuria precedes overt urinary tract infection and
deterioration of renal function in autosomal dominant polycystic kidney
disease. BMC Nephrol. 2013;14:1.
Woon et al. BMC Nephrology    Page 15 of 16
98. Lacquaniti A, Chirico V, Lupica R, Buemi A, Loddo S, Caccamo C, et al.
Apelin and copeptin: two opposite biomarkers associated with kidney
function decline and cyst growth in autosomal dominant polycystic kidney
disease. Peptides. 2013;49:1–8.
99. Spithoven EM, Meijer E, Boertien WE, Sinkeler SJ, Tent H, de Jong PE, et al.
Tubular secretion of creatinine in autosomal dominant polycystic kidney
disease: consequences for cross-sectional and longitudinal performance of
kidney function estimating equations. Am J Kidney Dis. 2013;62:531–40.
100. Thong KM, Ong ACM. The natural history of autosomal dominant polycystic
kidney disease: 30-year experience from a single centre. QJM.
2013;106:639–46.
101. Higashihara E, Nutahara K, Okegawa T, Shishido T, Tanbo M, Kobayasi K,
et al. Kidney volume and function in autosomal dominant polycystic kidney
disease. Clin Exp Nephrol. 2014;18:157–65.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Woon et al. BMC Nephrology    Page 16 of 16
